Objectives To identify and synthesize evidence on the diagnostic accuracy of FE NO for asthma in adults. Materials and Methods Systematic searches (nine key biomedical databases and trial registers) were carried out on November 2014. Records were included if they recruited patients with the symptoms of asthma; used a single set of inclusion criteria; measured FE NO 50 in accordance with American Thoracic Society guidelines, 2005 (off-line excluded); reported/allowed calculation of true-positive, true-negative, false-positive and false-negative patients as classified against any reference standard. Study quality was assessed using QUADAS II. Meta-analysis was planned where clinical study heterogeneity allowed. Rule-in and rule-out uses of FE NO were considered. Results A total of 4861 records were identified originally and 1312 in an update. Twentyseven studies were included. Heterogeneity precluded meta-analysis. Results varied even within subgroups of studies. Cut-off values for the best sum of sensitivity and specificity varied from 12 to 55 p.p.b., but did not produce high accuracy. 100% sensitivity or 100% specificity was reported by some studies indicating potential use as a rule-in or rule-out strategy. Conclusions and Clinical Relevance FE NO 50 had variable diagnostic accuracy even within subgroups of studies with similar characteristics. Diagnostic accuracy, optimal cut-off values and best position for FE NO 50 within a pathway remain poorly evidenced.
Introduction
The fraction of nitric oxide in exhaled breath ( FE NO) is elevated in some patients with asthma as a result of interleukin (IL)-13-induced induction of nitric oxide synthase in airway epithelium. Elevated values are independent of allergy [1] , but are associated with eosinophilic airway inflammation and with responsiveness to treatment with inhaled corticosteroids (ICS) [2, 3] , and may therefore be a useful test in the diagnosis and management of asthma. The availability of hand-held monitors improves the practicality and affordability of including a FE NO test in diagnostic pathways within primary care. However, the role for FE NO within such pathways is currently unclear. As FE NO is largely a marker of type-2 cytokine-mediated inflammation, it is unlikely to be useful as an absolute test for asthma as not all asthmatics have this feature. Some current guidelines and commentaries suggest its best use may be to identify those patients who will respond to ICS therapy [4] [5] [6] . Indeed, there is increasing interest in the concept of diagnosing steroid-responsive disease as its own classification across what are currently defined as distinct airway disorders [i.e. asthma, chronic obstructive pulmonary disease (COPD)]. However, to date, national and international guidelines and diagnostic pathways [4, 5, [7] [8] [9] do not aim to diagnose steroid-responsive disease according to a classification, but aim to diagnose asthma according to its classical definition. As such, the focus of this work was on the use of FE NO for the diagnosis of asthma, with data relating to its use to identify steroid-responsive disease included de facto.
Currently, there is no clear consensus relating to the cut-off between normal and abnormal FE NO 50 levels, or whether FE NO 50 should be used as a rule-in test, a ruleout test or both. In clinical practice, choosing different cut-off levels will alter sensitivity, specificity and positive and negative predictive values (NPVs). As we reviewed the evidence, it became clear that study designs varied greatly in terms of populations recruited and reference standards used; as sensitivity and specificity can theoretically vary depending on the characteristics of the population recruited, and as there is no definitive reference standard for asthma (and thus different reference standards will also affect sensitivity and specificity), the evidence base needed careful consideration. We have attempted to order the evidence sensibly to account for these variations and to enable readers to focus on the data that most closely match their own clinical scenario. However, the complexity of the evidence base makes both the presentation of results and the making of overall recommendations challenging, and highlights the need for critical thought in clinical applications.
Whilst there are many expert reviews relating to the use of FE NO in the diagnosis of asthma [10] [11] [12] [13] [14] [15] [16] , we are only aware of three systematic reviews. Two were only briefly reported [5, 17] , and one had only a limited scope ( FE NO to diagnose exercise-induced bronchoconstriction; EIB) [18] . In comparison, our publication is the first to systematically search for and codify the evidence base, and as such provides a clear and comprehensive framework on which future research can be based. Further, through our synthesis, we aimed to qualitatively consider the question of where in the diagnostic pathway FE NO may best be placed, and what cut-off points may be best for its use as a rule-in and rule-out test.
Materials and methods

Context
We were commissioned to conduct a systematic review of the evidence relating to the use of FE NO in both asthma management and diagnosis as part of the National Institute of Health and Care Excellence (NICE) Diagnostic Appraisal Programme. The appraisal focussed specifically on the hand-held monitors NIOX MINO, NIOX VERO and NObreath, but we reviewed evidence produced using any on-line FE NO monitoring device, including chemiluminescent and electrochemical devices. We have published two reviews from this project elsewhere, one on FE NO for management in adults [19] and one in children [20] . We have also published an Health Technology Assessment (HTA) monograph, which included a review of the comparability of the devices, the two reviews on management, two reviews on diagnosis (in children and adults) and a costeffectiveness analysis [21] . In that report, we narrowed the evidence base to studies with relevance to UK practice. Here, we report an update on that work, and we do not restrict our inclusion criteria by relevance to UK practice, leading to a much wider evidence base. Notably, NICE produced draft guidelines in 2015 [22] , and an update in 2016 [23] , based on a separate piece of work with a different search strategy and different inclusion criteria. Figure 1 presents some possible locations for FE NO within a simplified diagnostic pathway (based on the UK BTS/SIGN guidelines) [24] , denoted by letters A to E. In each position, FE NO could be used as a rule-in test (high specificity) or a rule-out test (high sensitivity). We have used this schema to order our findings and to consider the clinical implications of different positions. One potentially useful position is to prevent referral of at least a proportion of patients to airway hyperresponsiveness (AHR), an unpleasant and costly test (positions C&D) with significant, and in rare cases severe, sideeffects. Equally, it could be used as described elsewhere [4, 5] to identify patients who should respond to ICS therapy (position B) and avoid 'false negatives' when using a trial of treatment, for example by identifying patients who may need higher doses of ICS to achieve a response, or who may not have complied with the trial of treatment. Of course, a test may have high specificity, but very poor sensitivity, meaning many patients with disease will be missed by a rule-in scenario, unless further tests are performed; similarly, highly sensitive tests may have poor specificity and in a rule-out scenario may fail to eliminate some subjects. For FE NO, the selection of the cut-off point dictates the balance between true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN). The downstream costs and consequences of each of these can in turn also affect the clinical utility and where best the balance between sensitivity and specificity lies.
Identifying the literature
Systematic searches were carried out between March 2013 and April 2013. Update searches were conducted in September 2013 and again in November 2014. The full strategy and an example from one bibliographic database are provided in Appendix S1, but in brief comprised searches of MEDLINE and MEDLINE In Process; EMBASE; Cochrane Library; Science Citation Index Expanded (SCIE); and Conference Proceedings Citation Index -Science (CPCI-S). Trial registers [ClinicalTrials.-gov; metaRegister of Controlled Trials; FDA Manufacturer and User Facility Device (MAUDE); and EuroScan International Network] were also searched in March 2013 and for both updates. The search comprised subject heading and free-text terms for NIOX MINO, NObreath and FE NO, combined with terms for asthma and lower respiratory tract symptoms. Additional searches for studies relating to NIOX VERO were conducted in August 2013, and terms relating to NIOX VERO included in the update searches. randomised controlled trial (RCT) and diagnostic study filters were applied.
Study selection
Studies were considered for inclusion in the review by one reviewer against the inclusion criteria summarized here, and provided in detail in the Appendix S2. Studies were included if they recruited participants presenting with the symptoms of asthma or reported a subgroup of such patients. FE NO 50 could be measured by any device (chemiluminescent or electrochemical), used in accordance with the ATS 2005 criteria [flow rate of 50 mL/s, exhalation time ≥ 10 s (adults)/≥ 6 s (children/adolescents)]. Off-line measurement techniques were excluded. Studies using a reference standard of any established diagnostic test or set of tests were eligible for inclusion and as such studies vs. ICS responsiveness were included, allowing an exploration of FE NO 50 for the identification of steroid-responsive disease. End-to-end studies (studies that recruit patients before diagnosis and follow them through to long-term clinical outcomes such as overall survival and quality of life, which are considered the highest quality primary research study design) and observational cohort studies as defined by the NICE methods guide [25] were eligible for inclusion. In the event, no end-to-end studies were found, and the review included only observational clinical validity (diagnostic accuracy) studies. These could be prospective or retrospective, cross-sectional or cohort designs, with one set of inclusion criteria (i.e. not case-control style studies), and could be either derivation (identification of cut-off value that best fits the data) or validation (cut-off value pre-specified) studies. Studies were included if they reported data that allowed the extraction or calculation of the numbers of patients who were TP, TN, FP and FN against the reference standard. Any clinical setting was acceptable. Conference abstracts were included where they provided sufficient data relating to population, reference standard, cut-off value used and diagnostic accuracy.
Data extraction
A data extraction form was developed following the guidelines given in the Centre for Reviews and Dissemination (CRD) Handbook [26] and the Cochrane Handbook [27] extracted fields are provided in Appendix S3 and included data relating to study characteristics, patient characteristics, reference standard, index tests and numerical data relating to diagnostic accuracy. Data were extracted from the studies by one of three reviewers and checked by a second reviewer. Discrepancies were resolved by discussion, with involvement of a third reviewer when necessary. Authors were contacted for key missing or unclear data. Data from multiple publications relating to the same group of patients were extracted and quality was assessed as a single study. Separate quality assessment was performed for subgroup analyses or use of a different reference standard within a study.
Quality assessment
Diagnostic accuracy studies were assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS 2) [28] , adapted to the specifics of the review (Appendix S4). All four of the QUADAS 2 risk of bias domains were assessed, namely patient spectrum (consecutive or random sample; case-control design avoided; inappropriate exclusions avoided); the conduct of the index test (blinded interpretation; pre-specified cut-off); the conduct of the reference standard test (appropriateness of the reference standard; blinded interpretation); and flow and timing of the study (time between index test and reference standard (to assess whether the underlying condition might have changed between tests, such that a different diagnosis would be made); same reference standard applied to all patients; inclusion of all patients in analysis). Each domain is given a summary score of high risk, low risk or unclear risk of bias. Questions relating to applicability were omitted as these were addressed through subgrouping of studies according to the patient spectrum and reference standard used. Quality assessment was conducted by one reviewer and checked by a second. A third reviewer was consulted in cases of disagreement.
Synthesis and analysis
A narrative synthesis was conducted and a hierarchical meta-analysis was planned where sufficient studies of acceptable clinical heterogeneity were available. Sources of clinical heterogeneity considered to be of importance included age, patient spectrum as indicated by inclusion criteria and baseline measurements [mean FE NO 50 , mean percentage of predicted forced expiratory volume in the first second (FEV1%), atopic status, smoking status], FE NO measurement device used and reference standard used. As already described, studies were subgrouped according to the patient spectrum (position in Fig. 1 ) and reference standard used as both factors can affect estimates of accuracy. For simplicity, bronchodilator reversibility testing (BDR) and trials of treatment with ICS were grouped together as airway reversibility tests (ARTs), with the test used specified in 50 as a rule-in or rule-out test, as the cut-offs with the highest sensitivity or specificity were not always reported, but were included in the analysis.
Results
A total of 4861 citations were identified by the initial search and 1312 by the updates. After exclusion of irrelevant titles and abstracts, the full texts of 430 citations were obtained, and of these, 27 studies (35 citations) were included in the review (Fig. 2) .
Study characteristics
Of the 27 studies included in the review, 15 studies (19 citations) were conducted in adults [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] , four studies (six citations) in adults plus adolescents [3, [48] [49] [50] [51] [52] , three studies (three citations) in all age groups [53] [54] [55] and five studies (seven citations) in an unspecified age range [56] [57] [58] [59] [60] [61] [62] . Key study and patient characteristics are presented in Table 1 . Mean ages ranged from 37 to 49 years, except four studies recruited younger cohorts [29, 30, 50, 52] and two recruited older cohorts [33, 38] . Gender ranged from 33% male to 85%. One study excluded atopic patients [30] , one recruited only atopic patients [40] , and all others ranged widely in between or did not report this characteristic. FEV1% was often not reported, but ranged from 89% to 113% where it was. Mean FE NO 50 at baseline was also often not reported, with the lowest mean at 15.4 p.p.b. [34] and the highest at 74.5 p.p.b. [31] . Most studies used chemiluminescent analysers (n = 14) [ [38, 39, 53, 60, 62] . Twelve studies did not specify whether corticosteroids were used by patients prior to or during testing [34, 36, 38, 39, 48, [50] [51] [52] [55] [56] [57] [58] [59] [60] [61] [62] , whilst corticosteroid use was either stopped (three studies) [33, 41, [44] [45] [46] [47] or patients who used them were excluded (11 studies) [3, 29-32, 37, 40, 42, 43, 53, 54] . One study had a mix of users and nonusers [35] . Due to these differences across all study and patient characteristics, clinical heterogeneity was judged to be high and a meta-analysis was not performed. The cut-offs used to diagnose asthma varied, but were most commonly within the 20-40 p.p.b. range. Some studies reported sensitivity and specificity for multiple cut-off points, whilst others either pre-specified the value or selected the value with the best sum of sensitivity and specificity (best sum cut-off).
Diagnostic accuracy results are presented in Table 2 in summary and in full in Appendix S7. Twelve subgroups were identified (grouped by position in the pathway and reference standard used), and for each, methodological quality ( Fig. 3 ) according to QUADAS 2 [28] and estimates of cut-offs and accuracy are described below.
Position A: Asthma symptoms, no previous tests (i) Reference standard of diagnostic pathway that included AHR and ART: There were seven studies in this category [3, 31-33, 44-46, 53, 54] . Methodological quality was mixed (Fig. 3) , with no study scoring particularly well. The index test domain scored high risk most often, as many studies did not use a predefined cut-off. Blinding of the index test scored well as it was usually performed before the reference standard. The reference standard domain and the flow and timing domain usually scored poorly due to poor reporting.
Cut-off values were pre-specified in two studies [31] [32] [33] (≥ 20 and 40 p.p.b.). Derived values for the best sum similarly ranged from 20 to 47 p.p.b. There was no pattern as to whether sensitivity was higher than specificity amongst any of these studies. A partial range of cut-off values was reported by three studies [3, [44] [45] [46] , but a full range by only two (see Appendix S7) [44] [45] [46] . In these, rule-out scenario cut-off values were 9 and 12 p.p.b., respectively, with sensitivities of 96% (specificity of 13%) and 85% (specificity of 24%). Rule-in scenario cut-off values were 71 and 76 p.p.b., with specificities of 97% (sensitivity of 18%) and 100% (sensitivity of 13%), respectively, although specificity of Citations identified through database searching original searches n = 4853
Update n = 1312
Additional citations identified through other sources original search n = 6
Citations screened by title original searches n = 4859 Update n = 1312
Full-text citations assessed for eligibility original search n = 405 Update search n = 25
Full-text articles excluded n = 395
Citations excluded by abstract original search n = 1280 Update search n = 220
Studies included in synthesis 27 studies (35 citations) in total
Citations screened by abstract original search n = 1685 Update n = 245
Citations excluded by title original search n = 3174 Update n = 1067 (iv) Reference standard of pathway plus long-term follow-up: This study [47] was a long-term follow-up of Schneider et al. [46] . Methodological quality was poor overall, mainly due to the loss of patients during follow-up, and the use of different follow-up methods for some patients. The results (cut-off of 26 p.p.b.) were very similar to the original article [46] , which used a reference standard of the pathway alone (Table 2 ).
Position A: Asthma symptoms plus one additional symptom (v) Reference standard of AHR: In this study [48] , patients had rhinitis with asthma symptoms. Only patient selection was at low risk of bias. The derived best sum cut-off (36 p.p.b.) was within the same range as other studies at position A, although accuracy was unimpressive at 77.8% sensitivity and 60% specificity. However, 100% sensitivity was achieved at 25 p.p.b. and 100% specificity at 100 p.p.b., and 90% specificity at 75 p.p.b.
Position C: Negative airway reversibility test
(vi) Reference standard of AHR: One study recruited patients who had a negative ART [37] , but all were army recruits (introducing spectrum bias as excludes certain ages, comorbidities, etc). Cut-offs from 10 to 30 p.p.b. were reported, which is unlikely to include the cut-off with the best specificity. The derived best sum cut-off was 32 p.p.b. (47% and 85%, respectively). A cut-off of 10 p.p.b. yielded 81% sensitivity (specificity of 39%), whilst the 30 p.p.b. cut-off yielded 82% specificity (sensitivity of 49%).
Position C or D: Referred for airway hyperresponsiveness
(vii) Reference standard of AHR: Two studies stated that patients were referred for AHR testing, but did not state for what reason [61, 62] , and one stated that patients were at a tertiary referral centre [38, 39] . Patients are assumed to be at position C or D. Studies were at unclear risk of bias due to poor reporting and selection of patients with data for both FE NO 50 and AHR tests [38, 62] . One study used mannitol [61] , whilst the other two used methacholine [38, 62] . Although none reported multiple cut-offs, specificity did reach 96.3% (sensitivity of 30.2%) at a cut-off of 47 p.p.b. in one study [61] . One other study reported similar sensitivity and specificity at an unknown cut-off (sensitivity of 33.3%, specificity of 84.8%) [38] . The third study reported a cut-off of 35 p.p.b. with sensitivity of 75% and specificity of 83.3% [62] .
Position E: Patients with normal spirometry (viii) Reference standard of AHR: one study [44, 45] analysed a subgroup of patients with normal spirometry and the symptoms of asthma. The study was of reasonable quality and only scored poorly due to not pre-specifying a cut-off point and using different reference standards.
Results at two cut-offs only were reported, with a specificity of 90% (sensitivity of 35%) at 46 p.p.b. and a sensitivity of 78% (specificity of 45%) at 16 p.p.b.
Position D: Patients with chronic cough negative for other conditions
Five studies recruited patients with chronic cough who had undergone tests for other conditions [e.g. gastrooesophageal reflux disease (GORD) medication response, X-ray, computed tomography (CT) scan], but without reaching a diagnosis [35, 36, 40, 42, [56] [57] [58] .
(ix) Reference standard of ART to ICS: Patients had normal chest radiographs or CT scans [35, 40] , or had not responded to GORD or upper airway cough syndrome treatments [36] . These studies assess the use of FE NO 50 at position D in the pathway, to replace or be used as well as one possible subsequent test. Key methodological weaknesses included the exclusion of smokers (spectrum bias) [35, 36] and a lack of clarity about the timing, sequence and blinding of tests. No study reported a range of cut-offs. Estimates were very similar in the two studies that excluded smokers [35, 36] , with similar optimal cut-offs (38 and 33.9 p.p.b.), high sensitivity values (90% and 94.7%) and reasonable specificity (85% and 76.3%, respectively). The third study (which also had 0% smokers but did not state they were specifically excluded) reported sensitivity and specificity in the opposite direction than expected for the low cut-off value of 20 p.p.b. (Table 2) .
(x) Reference standard of ART and AHR: One study recruited patients with normal chest radiograph and CT scan [42] , whilst another recruited patients with normal chest radiograph [56] [57] [58] . Key methodological weaknesses included a lack of information relating to the timing, sequence and blinding of tests. A range of cutoffs was not reported. The derived best cut-offs were similar to the previous studies at 38.8 and 40 p.p.b. However, specificities (91.3% and 86%, respectively) were higher than sensitivities (79.2% and 75%, respectively).
Other studies (xi) Eight studies did not fall into the above categories. Arora et al. [29] have limited generalizability due to the cohort recruited (Table 1) . Mathew et al. recruited patients with normal spirometry and no evidence of reversibility, a difficult group to place on our generic pathway as patients with normal spirometry would not normally undergo reversibility testing (Fig. 1) . Pedrosa et al. [50, 51] and Schleich et al. [43] recruited patients with normal spirometry or negative ART (implying fixed airflow obstruction in some), which is likewise a difficult group to place as it mixes patients from two positions in the pathway. The diagnostic accuracy of FE NO 50 in these groups is presented in Table 2 and in Appendix S7.
The three remaining studies reported useful results. Bobolea et al. [55] recruited patients who had a negative methacholine challenge test (MCT), to see whether there might be evidence of asthma despite this. The reference standard was adenosine challenge and the study quality was good except for information about blinding and timing of tests. FE NO 50 demonstrated a sensitivity of 100% (specificity of 29.2%) at a cut-off of 30 p.p.b. El Halawani et al. [30] recruited patients suspected of EIB and used a reference standard of exercise challenge testing. Study quality was unclear/low as patients over 40 years were excluded to avoid patients with emphysema (spectrum bias), and missing details about timing, blinding and sequence of tests. FE NO 50 demonstrated 100% sensitivity (specificity of 31%) at a cut-off of 12 p.p.b. Sastre et al. [41] recruited patients with suspected occupational asthma and used a reference standard of a specific inhalation challenge. In this case, specificity was reasonable at 80% (sensitivity of 60%) at a cut-off of 25 p.p.b.
(xii) FE NO 50 used in conjunction with another test: Three studies reported results for FE NO 50 in conjunction with another test [31, 43, 54] . In Cordeiro et al. [54] , a positive test was FE NO 50 > 27 p.p.b. and/or ART. The reference standard, ART and/or AHR, introduced incorporation bias as ART formed part of both the index test and the reference standard. Diagnostic accuracy improved compared to FE NO 50 alone. In Schleich et al. [43] , a positive index test was FEV1 ≤ 101% with FE NO 50 > 34 p.p.b. The reference standard was AHR by MCT. The patients selected were a mix of positions B and C. Addition of FEV1 ≤ 101% improved specificity, but decreased sensitivity (Table 2 ). In Fortuna et al. [31, 32] , using sputum eosinophilia in conjunction with FE NO 50 increased specificity from 64% to 76%; specificity was not reported. They also reported that the addition of bronchodilator test and lung function tests did not increase accuracy, but actual data were not reported.
Discussion
This systematic review of the diagnostic accuracy of FE NO 50 for asthma included 27 studies in adults/all ages. Across this heterogeneous literature, it is extremely difficult to draw any robust conclusions about optimal cut-off points, whether accuracy varies according to patient populations and reference standards, where FE NO 50 should be placed within a diagnostic pathway, or whether FE NO 50 would be best used as a rule-in test or a rule-out test. Several categories of studies were identified (i-xii), each of which relates to a specific clinical scenario. Across these categories, no studies reported 100% accuracy, although rule-in and rule-out scenarios appeared more promising with high and perfect sensitivities or specificities often being reported.
Discussion of results
Estimates of accuracy in category i-iv studies ( FE NO 50 to replace the whole pathway in newly presenting patients, position A) varied. Even at its best, FE NO 50 could not be considered an adequate replacement for the whole diagnostic pathway as many patients would be incorrectly diagnosed. As a rule-in/rule-out test, high cut-off values (41 p.p.b.) for FE NO 50 achieved high specificity (> 90%), indicating it could be used as a rule-in test, but the best sensitivity reported was less good (81.5-96%, cut-off values of 9-25 p.p.b.), indicating only moderate potential as a rule-out test. Despite the fact that not all asthmatics have eosinophilic inflammation, three studies reported 100% sensitivity [30, 47, 55] . However, all were from relatively small samples (n < 50) and highly selected populations, which may account for the unexpected results.
The category v study recruited patients with rhinitis and asthma symptoms and reported excellent sensitivity (100% at 25 p.p.b.) and specificity (100% at 100 p.p.b.). There is not enough evidence to conclude there is better accuracy in patients with rhinitis, due to the small number of studies (n = 1).
Category vi and vii studies assessed the use of FE NO 50 before or in place of AHR testing. This position was identified a priori as potentially the most useful position for FE NO 50 for use in primary care to avoid the need for referral to a secondary care facility for unpleasant and expensive AHR testing in at least a proportion of patients, by either ruling asthma in or out. None of the studies reported a full range of cut-off values. High specificity (96.3%, sensitivity 30%) was reported in one study [60] , using a cut-off of 47 p.p.b., indicating the potential for FE NO 50 to be a useful rulein test at this point, although the small evidence base precludes a firm conclusion.
Categories ix and x recruited patients with chronic cough who tested negative for imaging tests such as X-ray or CT scan (position D). Some tested FE NO 50 against a reference standard of ICS responsiveness (trial of treatment). A trial of ICS is an unlikely test at this point, according to some guidelines [24] , but could be a useful test for steroid-responsive disease in these patients. A trial of ICS treatment can lead to misdiagnosis of asthma through spontaneous remission of symptoms, through subjective interpretations of response or through poor adherence to ICS treatment or need for higher ICS dose. As such, these studies are difficult to interpret if, for example, FE NO 50 is better at identifying patients with truly steroid-responsive disease than a trial of treatment. Other studies tested against AHR, which is a likely next test at least in some jurisdictions; avoiding this test has advantages as already discussed. As no study reported a range of cutoffs, the full potential of FE NO 50 as a rule-in/rule-out test at this point is unclear, although good sensitivity vs. ICS responsiveness (90%, 94.7%) [35, 36] and good specificity vs. AHR (91.3%) [46] were reported.
Category viii assessed the use of FE NO 50 before or in place of referring patients to tests for other conditions (position E). We had not explicitly identified this position a priori, but believe it may be a useful position as it could, if used in primary care, hasten the correct diagnosis, through accelerated and more appropriate patient pathways. Only one study conducted this analysis [44, 45] and a full range of cut-off values was not reported, although a specificity of 90% at 46 p.p.b. and a sensitivity of 78% at 16 p.p.b. are promising.
In category xi, very specific uses of FE NO 50 were tested. The small evidence base suggests FE NO 50 could be used successfully (100% sensitivity) in patients who had a negative MCT to identify patients who would score negatively by adenosine challenge testing [55] and for those under 40 years of age referred for exercise challenge testing [30] . The other study in this category showed 80% sensitivity at a derived cut-off of 25 p.p.b.; promising better results may be achieved at different cut-offs. As such, FE NO 50 appears to have the potential to be a useful rule-out test before these very specific bronchial challenge tests. Category xii studies were, in theory, useful to construct steps mid-way in the diagnostic pathway. However, the reported scenarios were limited and not useful for this purpose.
Strengths and limitations of this study
This study is the first fully reported systematic review of the diagnostic accuracy of FE NO 50 in asthma. It benefits from a high-quality, extensive search strategy, quality assessment using the QUADAS-2 checklist and double data checking by the authors. Whilst a large number of studies were identified, the results remain inconclusive. This is in part due to the methodological weaknesses of the primary studies themselves, poor reporting of key methodological points and a lack of reporting of a full range of cut-off values. It is also due to the variability in results between studies. Ideally, the impact on estimates of diagnostic accuracy of factors such as age, severity at inclusion, atopy, smoking status, ICS use and FE NO device used would have been investigated, but the heterogeneity between these factors as well as in the major characteristics of study population and reference standard made any sensitivity or subgroup comparisons between studies with a given characteristic problematic. As such, no sensitivity analyses were conducted and the causes of heterogeneity in results remain largely uninvestigated.
Of particular note was the low level of reporting of atopic status and corticosteroid use prior to testing. Both factors have been shown to affect FE NO levels, so it is surprising that they were not more carefully considered by study authors. For atopy, one study reported results both for the whole recruited cohort and for a subgroup of patients who had atopy [37] . Whilst the overall accuracy was similar in both cohorts (area under the curve 0.69 (95% CI 0.6-0.775) and 0.68 (95% CI 0.53-0.8), respectively), the cut-off with the highest sum of sensitivity and specificity was higher in non-atopic patients than in atopic patients (32 vs. 26 p.p.b., respectively), which is not as expected. Equally, an exploratory analysis comprising a simple ordering of studies according to % atopic patients did not reveal a trend towards lower cut-offs (see Appendix S7) for studies that recruited a higher proportion of atopic patients. Reasons for this remain unclear, although the heterogeneity in other characteristics may play a part. For corticosteroid use, the studies that did not mention whether this was stopped prior to testing may have recruited patients before any treatments were prescribed, but this was largely unclear. The study that included patients who were on ICS as well as patients who were not [35] aimed to identify patients who would respond to an increase in or new treatment with ICS, so the inclusion of those already treated with ICS was appropriate to the aim of that study. The mean FE NO 50 The use of FE NO in the diagnosis of asthma or steroidresponsive disease?
The variability of results seen in our review does not detract from the potential that FE NO has to make a useful contribution in the diagnosis of asthma evidenced by the very good specificities and sensitivities reported in some studies. Some current thinking about asthma is moving towards the identification of steroid-responsive disease rather than classical asthma diagnosis. For the identification of patients with asthma who will respond to ICS, a recent international review [4] (high), patients should be considered asthmatic and prescribed a moderate dose of ICS therapy (rule-in asthma). The ATS guidelines [5] reported that levels below 25 p.p.b. indicate a low likelihood of eosinophilic inflammation and ICS responsiveness and levels above 50 p.p.b. indicate a high likelihood. It also reports similar cut-offs for ICS responsiveness. Our review found only four studies that used ICS responsiveness as the reference standard [35, 36, 40, 49] . None reported 100% sensitivity or specificity, despite one study reporting a wide range of cut-offs (25-150 p.p.b.). Two studies reported highest sum cut-offs of 20-25 p.p.b., with one reporting poor sensitivity (53%) and specificity (63%) [40] and one reporting somewhat better values at 83% and 57% [49] , respectively. The latter study also reported a cutoff of 50 p.p.b. and showed almost inverse values of 58% and 80%, respectively [48] . Better values were reported by the other studies, indicating good overall accuracy, with sensitivities and specificities of 90% and 85%, and 95% and 76%, respectively, at higher cut-offs of 38 and 33.9 p.p.b. [35, 36] . All four studies are limited in terms of generalizability (three recruited patients with chronic cough who were negative for tests for other conditions [35, 36, 40] , and in one case some patients were already on ICS treatment [35] and one recruited adults and adolescents with the symptoms of asthma [49] ). The imperfect reference standard, as previously discussed, may account for some of the differences between index test ( FE NO 50 ) and reference standard (ICS responsiveness). Whilst the two guidelines recommended specific cut-offs for identifying steroidresponsive disease, the results of our review do not lend themselves to making such a recommendation. This is in part due to the more restrictive inclusion criteria we have applied. In particular, this means we do not include studies cited in the guidelines which are on paediatric [63] [64] [65] patients, COPD [66] [67] [68] [69] [70] and diagnosed asthmatics [71] . Given this smaller evidence base, we conclude that the use of FE NO 50 as a marker of steroid-responsive disease in adult patients with the symptoms of asthma remains very much understudied.
When considering FE NO 50 to diagnose asthma, it was interesting to see that results did not obviously differ between categories, with very similar ranges of cut-offs and accuracies across them all. This was surprising and may indicate that the theoretical assumption that patient spectrum and reference standard used would affect accuracy estimates does not hold. Equally, any differences may be obscured by the large amount of 'noise' from confounders between studies and relatively small number of studies in any one category. However, because of this generality of results, and because FE NO 50 may be used at any point in a diagnostic pathway to indicate asthma, an exploration of which cut-offs may provide the best sensitivity and specificity in any situation was conducted using all available studies (Appendix S7). When study results were ordered according to cut-offs, studies using 20-25 p.p.b. did not consistently deliver good sensitivity (range 36-100%). Sensitivities above 80% were only consistently delivered by studies with cut-offs ≤ 12 p.p.b., and sensitivities above 70% were only consistently provided by studies with cut-offs ≤ 15 p.p.b. This perhaps suggests that the cut-off point for 'normal' should be set somewhat lower if FE NO 50 is used in a pathway to diagnose asthma as opposed to steroid-responsive airway disease. Similarly, results suggested that a higher cut-off than 50 p.p.b. may be more likely to consistently deliver high levels of specificity, with specificities ≥ 90% only consistently being reported in studies with cut-offs > 70 p.p.b.
Research recommendations
The benefits and harms to patients of being TP, TN, FP or FN remain largely unquantified and could affect which cut-off is preferred; the consequences of being wrongly diagnosed (either FP or FN) may mean it is preferable to sacrifice some sensitivity or specificity to minimize these consequences. As part of the wider project for this review, a cost-utility analysis was planned with one aim being to ascertain the best cutoff to use by modelling the consequences of each category. However, the evidence base was inadequate to populate such a model, mainly due to the lack of a full range of cut-offs being available and to the lack of data relating to each individual step in the pathway. To address this, future study authors should aim to report a full range of cut-off values. The best use of FE NO in a diagnostic pathway could be investigated using a study design where all diagnostic tests are given to all patients (as index tests) and different algorithms are modelled in a cost-utility analysis. This may allow the best position for FE NO to be assessed taking into account costs, benefits and harms.
Problems with the reference standard currently hamper all studies in this review. One study [47] attempted to surmount this issue through long-term follow-up of patients, but lost a large proportion of patients to follow up which may have introduced bias. Future study designs could include intensive long-term follow-up. Simultaneously, researchers could consider the capture of long-term clinical outcomes in end-to-end studies (considered the highest standard in the NICE evidence hierarchy) [25] , which would be directly useful in costeffectiveness models.
Another key research question is whether diagnosis of steroid-responsive disease is a better diagnostic target than asthma. Any new consensus regarding this may necessitate a different evidence base including wider populations (e.g. patients with symptoms of airway obstruction) and different reference standard methods (e.g. that aim to address adherence and dose issues when using a trial of ICS treatment). Publication checklists such as STARD [72] would facilitate better reporting and better assessment of methodological quality. Until high-quality evidence is available, the balance of costs and clinical benefits of the use of FE NO can only be assumed through clinical interpretation.
To conclude, this review reports a large and heterogeneous evidence base of high to moderate, and often unclear, risk of bias. Study designs do not allow a full assessment of the clinical impact of FE NO 50 when used in a pathway. Estimates of diagnostic accuracy and cut-off values for the diagnosis of asthma by its current definition varied greatly, even within groups of similar studies, probably due to heterogeneity in multiple study and patient characteristics, and study quality. Whilst optimal cut-off values often failed to produce impressive accuracy, very high sensitivities and specificities were reported at low and high cutoffs in several studies, indicating FE NO 50 could be a useful rule-in and/or rule-out test. However, the diagnostic accuracy, cut-off values that should be used and optimal position for FE NO 50 within a pathway remain poorly evidenced.
